Literature DB >> 11751785

The in vitro activity of BMS-284756, a new des-fluorinated quinolone.

T M A Weller1, J M Andrews, G Jevons, R Wise.   

Abstract

The in vitro activity of BMS-284756 (previously T-3811ME), a des-fluoro(6) quinolone, was investigated and compared with those of six other antimicrobial agents. Susceptibility tests were performed on 919 Gram-positive, Gram-negative (including nine quinolone-resistant Escherichia coli) and anaerobic bacteria, three Chlamydia isolates and four Mycobacteria spp. BMS-284756 was marginally less active against the Enterobacteriaceae, but was the most active quinolone against staphylococci, enterococci and peptostreptococci. Against Streptococcus pneumoniae, BMS-284756 and gemifloxacin were more active than other quinolones. The MIC(90) of BMS-284756 was > or = 2 mg/L for the following bacteria: E. coli (MIC(90) 16 mg/L), Acinetobacter spp. (8 mg/L), Pseudomonas aeruginosa (64 mg/L) and Enterococcus faecium (4 mg/L). The MIC of BMS-284756 for Mycobacterium spp. was within one dilution of the MIC of ciprofloxacin. BMS-284756 was markedly more active than ciprofloxacin against the Chlamydia isolates tested.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751785     DOI: 10.1093/jac/49.1.177

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.

Authors:  Yuichi Fukuda; Katsunori Yanagihara; Hideaki Ohno; Yasuhito Higashiyama; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Yohei Mizuta; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Ken'ichi Nakao; Kunitomo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

4.  Factor analysis of microbiological activity data and structural parameters of antibacterial quinolones.

Authors:  Marcin Koba; Tomasz Baczek; Katarzyna Macur; Leszek Bober; Teresa Frackowiak; Adam Buciński; Danuta Rystok-Grabska; Jolanta Stasiak; Katarzyna Koba
Journal:  J Mol Model       Date:  2009-07-15       Impact factor: 1.810

5.  In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.

Authors:  A Liebetrau; A C Rodloff; J Behra-Miellet; L Dubreuil
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.

Authors:  María-Isabel Morosini; Elena Loza; Rosa del Campo; Felisa Almaraz; Fernando Baquero; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

7.  Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  In vitro activities of new antimicrobials against Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Sung H Choi; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.

Authors:  Raymond P Smith; Aldona L Baltch; William J Ritz; Andrea N Carpenter; Tanya A Halse; Lawrence H Bopp
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.

Authors:  K J Christiansen; J M Bell; J D Turnidge; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.